webinar register page

Webinar banner
NPA Journal Club - Entyvio vs. Humira for Ulcerative Colitis. Speaker Shelby Dick, PharmD, PGY-1 Option Care Health
Ulcerative Colitis is a type of inflammatory bowel disease in which long lasting inflammation and ulcers lead to many debilitating symptoms such as diarrhea, abdominal pain, and rectal bleeding. Adalimumab (Humira) has been the mainstay of monoclonal treatment for Ulcerative Colitis due to the lack of head- to-head trials comparing it to other therapies. This is first head-to-head trial comparing the safety and efficacy of vedolizumab (Entyvio) versus adalimumab (Humira) in patients with moderate-to-severe Ulcerative Colitis.

Mar 5, 2020 02:00 PM in Central Time (US and Canada)

* Required information